Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML

NCT05184842 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia

Interventions

DRUG: Venetoclax
DRUG: Decitabine

Sponsor

Montefiore Medical Center

Collaborators

[object Object]
[object Object]
[object Object]